Table 3 |
|||
|
Primary and secondary endpoints |
|||
|
UFH (n = 20) |
UFH + tirofiban (n = 20) |
P value |
|
|
|
|||
|
Platelet/Monocyte counts at the end of CRRT |
|||
|
Platelet count, × 109/L, mean ± SD |
87 ± 41.1 |
158 ± 45.3 |
0.001 |
|
Monocyte count, × 106/L, mean ± SD |
945 ± 77.3 |
1,394 ± 151 |
0.012 |
|
Platelet-monocyte aggregates as a percentage, mean ± SD |
27.5 ± 9.3 |
3.9 ± 2.1 |
0.001 |
|
Bleeding events during CRRT |
|||
|
Minor bleeding, number |
2 |
1 |
0.560 |
|
Major bleeding, number |
0 |
0 |
1 |
|
Platelet transfusions during CRRT |
|||
|
Platelet units per patient per day, mean ± SD |
0.05 ± 0.02 |
0 |
0.016 |
|
Outcome |
|||
|
Intensive care unit mortality rate, number (percentage) |
8 (40) |
7 (35) |
0.752 |
|
Hospital mortality rate, number (percentage) |
8 (40) |
7 (35) |
0.752 |
|
SAPS II predicted mortality rate as a percentage |
36.9 |
41.4 |
- |
|
Observed-to-expected mortality ratio |
1.08 |
0.85 |
- |
|
95% confidence interval for the observed-to-expected mortality ratio |
0.46, 1.97 |
0.34, 1.59 |
- |
|
|
|||
|
Values are presented as number of patients or mean ± standard deviation (SD). CRRT, continuous renal replacement therapy; SAPS, Simplified Acute Physiology Score; UFH, unfractioned heparin. |
|||
|
Link et al. Critical Care 2008 12:R111 doi:10.1186/cc6998 |
|||
